London stocks ended Friday in negative territory, weighed down by losses in pharmaceutical shares and a surprise slowdown in ...

GlaxoSmithKline is opening a £10 million artificial intelligence (AI) research hub in King’s Cross, London, according to a press report. The area is being reimagined as a life sciences and ...

UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GlaxoSmithKline (GSK) is to collaborate with the Francis Crick Institute, a new powerhouse of academic- and charity-funded biomedical research based in London. The new partnership is expected to ...

Jitters over the health of the UK economy have been fuelled by today’s weaker-than-expected GDP release.September’s 0.1% ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase 3 trial of Blenrep (belantamab mafodotin) in combination with bortezomib ...